October 01, 2014 9:47 AM ET


Company Overview of Argolyn Bioscience, Inc.

Company Overview

Argolyn Bioscience, Inc., a biotechnology company, discovers and develops peptide drug candidates to treat psychosis, pain, and other serious diseases and disorders. The company’s products are based on amino acid analog substitution technology. The company's products include ABS201 for schizophrenia and ABS212 for pain. Argolyn Bioscience, Inc. was incorporated in 2002 and is based in Durham, North Carolina. Argolyn Bioscience, Inc. is under liquidation.

2530 Meridian Parkway

Suite 200

Durham, NC 27713

United States

Founded in 2002





Key Executives for Argolyn Bioscience, Inc.

Chief Executive Officer and President
Age: 64
Founder and Chief Scientific Officer
Executive Director
Age: 70
Chief Medical Officer and Advisor
Age: 65
Chief Development Officer
Age: 63
Compensation as of Fiscal Year 2014.

Similar Private Companies By Industry

Company Name Region
Embolx, Inc. United States
Clarion Research Group, Inc. United States
Gemini Bio-Products, Inc. United States
Holganix, LLC United States
FTA Bioscience, LLC United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact Argolyn Bioscience, Inc., please visit --. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.